Cognition 50 items
CETP genotype, cognition and the questions obicetrapib inherited.
Studies
- Genetically lower CETP activity reduces dementia risk in a 1,091,775-person Mendelian randomization meta-analysis (Alzheimers Dement 2025)
- BROADWAY substudy: obicetrapib cuts p-tau217 rise by a placebo-adjusted 20% in ApoE4/E4 carriers with cardiovascular disease (J Prev Alzheimers Dis 2026)
- Genetic CETP deficiency, mimicking a lifetime of CETP inhibition, trades a lower cardiovascular death and MI risk for a matching rise in AMD (JAMA Cardiol 2022)
- In BROADWAY, obicetrapib slows p-tau217 progression, most in APOE4 carriers, positioning CETP inhibition against Alzheimer's disease (Am J Prev Cardiol 2026)
- Drug-target Mendelian randomization finds lower CETP concentration cuts Lewy body and Parkinson's dementia risk, especially in APOE-e4 carriers (Alzheimers Res Ther 2024)
- Reducing CETP activity with evacetrapib preserves memory in an Alzheimer's mouse model, independent of amyloid or tau markers (EMBO Mol Med 2026)
- CETP inhibitors reframed: from raising HDL to lowering atherogenic lipoproteins and improving glycaemic control, with obicetrapib the current lead (Circ Res 2026)
- CETP renaissance: a review maps obicetrapib reach beyond LDL-C into dementia, glycaemic control, sepsis and kidney function (Curr Atheroscler Rep 2026)
- CETP inhibition as a longevity pathway: apoB lowering, not HDL raising, is the mechanism, with signals in diabetes, dementia and kidney disease (Curr Opin Lipidol 2024)
- Beyond the heart: a review finds no excess macular degeneration risk across over 70,000 CETP-inhibitor trial patients, and surveys links to dementia, diabetes and sepsis (Pharmacol Res 2023)
- A JAMA study links CETP valine-405 homozygosity to slower memory decline and lower dementia incidence (JAMA 2010)
- A longevity-associated CETP genotype preserves cognitive function in two independent cohorts (Neurology 2006)
- The two faces of CETP inhibitors: a review argues the therapeutic case has shifted from raising HDL-C to lowering apoB, with obicetrapib as proof (Curr Opin Lipidol 2025)
- Mendelian randomization links CETP inhibition to lower lacunar stroke risk via cerebral small vessel disease genetics (Brain 2025)
- Mendelian randomization links CETP inhibition and elevated LDL cholesterol to Lewy body dementia risk (Prog Neuropsychopharmacol Biol Psychiatry 2025)
- Review examines how CETP and peripheral lipoproteins may contribute to vascular cognitive impairment and dementia (Mol Neurodegener 2023)
- Evacetrapib crosses the blood-brain barrier within 30 minutes, positioning CETP inhibitors as candidates for Alzheimer's disease (Front Pharmacol 2023)
- CETP activity raises brain cholesterol levels by reducing cholesterol efflux in transgenic mice (J Lipid Res 2022)
- CETP haplotypes predict whether lipophilic statins help or harm cognition in Alzheimer's disease (J Alzheimers Dis 2022)
- The CETP I405V polymorphism is an independent risk factor for Alzheimer's and vascular dementia in a Southern Italian cohort (J Alzheimers Dis 2018)
- A well-powered Mendelian randomization study finds CETP-driven HDL cholesterol is not associated with Alzheimer's disease risk (Alzheimers Dement 2018)
- Higher serum CETP independently predicted mild cognitive impairment in type 2 diabetic patients (J Alzheimers Dis 2016)
- A protective CETP variant buffers the memory-decline effect of APOE4 in older adults (Neurobiol Aging 2016)
- Cache County Study links CETP I405V valine allele to slower cognitive decline in 4,486 older adults (Neurobiol Aging 2015)
- Meta-analysis links the CETP rs5882 A allele to increased Alzheimer's disease risk in Caucasians (DNA Cell Biol 2014)
- The CETP rs5882 variant predicts white matter microstructure, with opposite effects in young versus older adults (Neurobiol Aging 2014)
- CETP I405V valine homozygosity is linked to better cognitive function after age 65 (Neurobiol Aging 2012)
- CETP polymorphisms are linked to brain structure and Alzheimer's risk in an APOE-dependent manner (Brain Imaging Behav 2012)
- Contradicting earlier reports, the CETP I405V polymorphism is linked to faster cognitive decline and higher Alzheimer's risk in a large US cohort (Aging Cell 2012)
- A CETP variant raises vascular dementia risk and lowers white matter lesion load, but only in APOE4 non-carriers (J Neural Transm 2009)
- The Rotterdam Study links CETP I405V VV genotype to increased Alzheimer's disease risk in APOE4 non-carriers (Neurogenetics 2007)
- The CETP C-629A promoter variant modifies the Alzheimer's disease risk conferred by APOE epsilon4 (J Neurol 2006)
- CETP genetic variants shape the lipid response to statins in Alzheimer's disease patients (Sao Paulo Med J 2025)
- A CETP variant is one of four factors in a nomogram predicting behavioral symptoms in Alzheimer's disease (Chin Med J 2024)
- CETP I405V II genotype linked to gray matter diffusion abnormalities in healthy older adults (J Neural Transm 2015)
- Meta-analysis finds CETP TaqIB genotype raises Alzheimer's risk only in APOE4-positive Asians, with no overall population association (Neurobiol Aging 2014)
- Review surveys the controversial CETP-atherosclerosis relationship and emerging roles in Alzheimer's disease, inflammation and obesity (IUBMB Life 2011)
- A well-powered study of CETP sequence variation finds no meaningful association with cognitive decline or dementia risk (Int J Mol Epidemiol Genet 2011)
- CETP variants shape cerebral and peripheral cholesterol metabolism but not Alzheimer's disease risk (Brain Res 2008)
- CETP genotype shows no association with cognitive function or lifetime cognitive change in the Scottish Mental Survey cohort (Neurosci Lett 2007)
- Two independent cohorts find no genetic association between CETP polymorphisms and late-onset Alzheimer's disease (Neurosci Lett 2005)
- CETP is localized to brain astrocytes, with increased expression in Alzheimer's disease gray matter (Acta Neuropathol 1995)
- CETP gene variants are associated with neuropsychiatric symptom severity in Alzheimer's disease (Braz J Psychiatry 2017)
- CETP gene variants linked to memory loss risk in a rural and tribal Indian cohort study (J Alzheimers Dis 2017)
- CETP TaqIB genotype raises HDL cholesterol but does not predict Alzheimer's disease risk in a Han Chinese cohort (Lipids Health Dis 2012)
- The CETP D442G variant shows a preliminary protective association against Alzheimer's disease in Chinese APOE4 carriers (Brain Res 2008)
- CETP TaqI B genotype shows no association with late-onset Alzheimer's disease or interaction with APOE4 or lipoprotein lipase (Neurosci Lett 2004)
- No CETP mass is detected in human cerebrospinal fluid, unlike LCAT and phospholipid transfer protein (J Lipid Res 2000)
- Cholesterol esterification is 16% slower in Alzheimer's disease, echoing earlier findings in Down's syndrome (Mech Ageing Dev 1994)
- Lymphocyte gene expression profiling finds CETP expression unaltered in Alzheimer's disease patients (Psychiatr Genet 2005)